Research Analysts Offer Predictions for BMY Q1 Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Equities research analysts at Zacks Research reduced their Q1 2026 earnings per share (EPS) estimates for shares of Bristol Myers Squibb in a report issued on Thursday, February 19th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $1.40 per share for the quarter, down from their prior forecast of $1.50. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s Q2 2026 earnings at $1.62 EPS, Q3 2026 earnings at $1.58 EPS, FY2026 earnings at $6.07 EPS, Q1 2027 earnings at $1.31 EPS, Q3 2027 earnings at $1.51 EPS, FY2027 earnings at $5.71 EPS and FY2028 earnings at $4.38 EPS.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.

BMY has been the subject of several other reports. Morgan Stanley reissued an “underweight” rating and set a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 17th. Barclays assumed coverage on Bristol Myers Squibb in a report on Thursday. They set an “overweight” rating and a $75.00 price target on the stock. Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $52.00 to $61.00 in a report on Monday, December 15th. Finally, Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Nine investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $60.19.

Bristol Myers Squibb Stock Up 0.6%

Shares of NYSE BMY opened at $60.66 on Friday. Bristol Myers Squibb has a 1 year low of $42.52 and a 1 year high of $63.33. The stock’s 50-day simple moving average is $56.22 and its 200-day simple moving average is $49.97. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The firm has a market cap of $123.53 billion, a price-to-earnings ratio of 17.58, a PEG ratio of 0.17 and a beta of 0.29.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Brighton Jones LLC boosted its stake in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the period. Sivia Capital Partners LLC lifted its holdings in shares of Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 2,786 shares in the last quarter. United Bank boosted its position in shares of Bristol Myers Squibb by 15.0% in the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after buying an additional 3,277 shares during the period. Avidian Wealth Enterprises LLC grew its holdings in shares of Bristol Myers Squibb by 20.9% during the second quarter. Avidian Wealth Enterprises LLC now owns 12,907 shares of the biopharmaceutical company’s stock valued at $597,000 after buying an additional 2,233 shares in the last quarter. Finally, Cullen Frost Bankers Inc. raised its position in Bristol Myers Squibb by 313.9% during the second quarter. Cullen Frost Bankers Inc. now owns 141,604 shares of the biopharmaceutical company’s stock valued at $6,555,000 after buying an additional 107,394 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.2%. The ex-dividend date was Friday, January 2nd. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Barclays initiated U.S. large‑cap biopharma coverage and included Bristol‑Myers Squibb among four preferred picks, arguing the sector could regain investor attention and highlighting BMY as a top choice. This institutional endorsement likely helped buying interest. Barclays launches U.S. biopharma coverage with four preferred picks
• Positive Sentiment: BMY reported completion of a mavacamten safety‑extension study update, which clarifies the long‑term safety profile for its hypertrophic cardiomyopathy program — a de‑risking event for a later‑stage asset and a potential long‑term revenue driver. BMY’s Mavacamten Safety Extension Wraps Up
• Positive Sentiment: Analyst/commentary pieces highlight BMY’s oncology franchise and new drug launches, noting cost cuts and a stronger 2026 outlook versus peers — reinforcing confidence in revenue stability and medium‑term growth. Bristol‑Myers Squibb: Oncology Franchise Remains A Core Strength
• Neutral Sentiment: Comparative analyst coverage (Zacks/Money pieces) argues BMY edges Merck in the 2026 setup due to product launches and cost actions — a relative positive versus peers but not new company‑specific catalysts. Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
• Neutral Sentiment: Coverage discussing an Iberdomide regulatory review and an AI partnership adds new angles to BMY’s mid‑cycle outlook; informative for pipeline expectations but not an immediate earnings swing. Iberdomide Review And AI Alliance Add New Angles To BMY Outlook
• Negative Sentiment: Zacks Research issued a series of downward revisions to several near‑term EPS estimates (notably Q1/Q2 2026 and FY2027 trims), which introduces caution around short‑term earnings momentum and could cap upside until upcoming results confirm guidance.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.